Opinion

Video

Vowst as a Potential Option for Patients With Recurrent C Difficile Infections

Key Takeaways

  • Vowst restores gut microbiome balance using live biotherapeutic products, differing from traditional antibiotic treatments for C. difficile infections.
  • Clinical trials showed Vowst significantly reduces recurrence rates, leading to FDA approval for recurrent C. difficile infection.
SHOW MORE

The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut bacteria to restore microbiome diversity, distinguishing itself from traditional antibiotics in preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment.

Related Videos
Dr Geoffrey Rutledge
3 experts are featured in this series.
5 experts are featured in this series
4 experts are featured in this series.
4 experts are featured in this series.
5 experts are featured in this series
1 expert is featured in this series.
3 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo